WINNIPEG, MANITOBA -- (MARKET WIRE) -- October 19, 2006 -- Medicure Inc. (TSX: MPH)(Amex:MCU), a cardiovascular focused biopharmaceutical company, today announced that the results of the Phase II MEND-CABG study will be presented at the Late Breaking Clinical Trial session of the 2006 Canadian Cardiology Congress (CCC) in Vancouver, British Columbia. The MEND-CABG study was completed in 2006 with the results demonstrating a statistically significant reduction in myocardial infarctions (CK-MB greater than 100 ng/ml) with MC-1 in patients undergoing coronary artery bypass graft (CABG) surgery.
